Valentina Mantua

Associate Director for Regulatory Science, U.S. Food and Drug Administration

Speaking at Psychedelic Healthcare Forum

FDA risk-mitigation (REMS) requirements for psychedelic therapies

Named at the forum as the FDA's representative on REMS (Risk Evaluation and Mitigation Strategy) requirements facing psychedelic therapies as they approach approval. Our source coverage of the forum didn't include the specific content of her remarks — this entry will be filled in once that portion of the reporting is verified.

Related on Altitude

Our coverage: the VA's 10-site rollout plan (same forum)

← Back to Conference Speakers